View the programme for the ESMO Symposium on Signalling Pathways in Cancer online or download a PDF file of the latest version
- To provide a basic introduction in the preclinical data relevant for understanding of functional mechanisms in the HER/EGFR family signalling
- To understand basic concepts of translating preclinical observations in the HER/EGFR family signalling into cancer clinics
- To provide an essential update on different aspects important for rational clinical development of the HER/EGFR targeting drugs and overcoming resistance
- To elaborate from the clinical perspective, in a range of solid tumours, on recent achievements and the data from currently ongoing clinical trials in targeting the HER/EGFR family
- Dissecting the tumour / cancer phenotype
- Clinical pharmacology concepts of targeted therapy and future approaches
- Mechanisms of resistance to HER targeting drugs
- Molecular characterisation and subtyping of common tumours
- Targeting the EGFR/HER family in colorectal, non-small cell lung, breast and gastric cancers
- Challenges for the future
Benefits of attending
- The programme is designed to accelerate the pace of translating novel and emerging cancer treatments to the bedside
- The lectures are designed to meet high educational standards and make an impact on personalised cancer therapy approaches
- An expert faculty will strive to enhance understanding of this signalling pathway and the complexities related to its targeting in a range of tumour types
- The relatively small size of the event will offer maximum networking opportunities
ESMO-MORA: The Symposium programme is accredited with 12 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. Find out more about ESMO-MORA accreditation.
CME: The ESMO Symposium on Signalling Pathways in Cancer 2016 is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS). The programme has been designated a maximum of 11 hours of European external CME credits. Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Find out how to convert EACCME credit to AMA credit.
The congress webcasts will include all sessions of the official programme, where speaker permission is granted, and will be available on this website and OncologyPRO for ESMO members.